Novel Inflammasome‐Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early‐Stage Non‐Small Cell Lung Cancer
Immune checkpoint inhibitors (ICI) for early‐stage non‐small cell lung cancer (NSCLC) have been approved to improve outcomes and reduce recurrence. Biomarkers for patient selection are needed. In this paper, we proposed an inflammasome‐based risk score (IRS) system for prognosis and prediction of IC...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |